Deficiency of interleukin-9 inhibits osteogenic potential in mice

doi:10.12307/2024.434

Abstract

Abstract: BACKGROUND: Mouse osteogenic potential is regulated by the JAK-STAT signaling pathway, and interleukin-9 can regulate multiple cellular functions through the JAK-STAT pathway, which has the potential to be a novel cytokine that regulates osteogenic potential.
OBJECTIVE: To investigate the effect of interleukin-9 deficiency on osteogenic potential in mice
METHODS: The femurs collected from 2-month-old wild-type and interleukin-9 knockout mice were subjected to Micro-CT scanning to analyze the changes in bone mass. Then, hematoxylin-eosin staining, Masson staining, and immunohistochemical staining of type I collagen were performed on the slices of the femurs of mice. Bone marrow cells from 2-month-old wild-type and interleukin-9 knockout mice were extracted for colony-forming assay and detection of osteogenic gene expression in bone marrow mesenchymal stem cells. To further verify whether interleukin-9 worked through the JAK-STAT pathway, the expression of STAT3 protein was detected by western blot.
RESULTS AND CONCLUSION: Micro-CT results showed the bone mass of interleukin-9 knockout mice decreased significantly compared with that of wild-type mice. In addition, the bone mineral density, bone volume fraction, trabecular number significantly decreased and trabecular separation markedly escalated in interleukin-9 knockout mice. The findings of hematoxylin-eosin staining were consistent with Micro-CT results. Interleukin-9 knockout mice had lower bone trabecular density. Type I collagen immunohistochemistry staining and Masson staining indicated the number of type I collagen positive osteoblasts was significantly reduced and the capacity of collagen formation was damaged in interleukin-9 knockout mice. The results of colony-forming assay indicated that the mineralization capacity of osteoblast in interleukin-9 knockout mice were significantly lower than that in wild-type mice. Western blot results showed that osteogenesis induction activated STAT3 signaling, and the pSTAT3 level in wild-type mice with osteogenic induction was significantly higher than that in interleukin-9 knockout mice with osteogenic induction. These findings suggest that interleukin-9 regulates osteogenesis through the JAK-STAT3 pathway and interleukin-9 deficiency inhibits osteoblast differentiation and function, which may lead to reduced bone mass in interleukin-9 knockout mice.

Key words: interleukin-9, osteoporosis, mesenchymal stem cell, osteogenic capability, osteogenic induction, osteogenic mineralization

CLC Number:

Wang Yi, Chen Chichi, Zhou Xichao, Shi Qin. Deficiency of interleukin-9 inhibits osteogenic potential in mice[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(26): 4178-4183.

Figures/Tables 7

References

[1] COMPSTON JE, MCCLUNG MR, LESLIE WD. Osteoporosis. Lancet. 2019;393(10169):364-376.
[2] EASTELL R, O’NEILL TW, HOFBAUER LC, et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069.
[3] Management of Osteoporosis in Postmenopausal Women: The 2021 Position Statement of The North American Menopause Society’’ Editorial Panel. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9):973-997.
[4] YU F, XIA W. The epidemiology of osteoporosis, associated fragility fractures, and management gap in China. Arch Osteoporos. 2019;14(1):32.
[5] ZHU X, BAI W, ZHENG H. Twelve years of GWAS discoveries for osteoporosis and related traits: advances, challenges and applications. Bone Res. 2021;9(1):23.
[6] ZEBAZE R, LIBANATI C, MCCLUNG MR, et al. Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis. J Bone Miner Res. 2016;31(10):1827-1834.
[7] CHAVASSIEUX P, CHAPURLAT R, PORTERO-MUZY N, et al. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment. J Bone Miner Res. 2019;34(9):1597-1608.
[8] LOTINUN S, KIVIRANTA R, MATSUBARA T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013;123(2):666-681.
[9] KRAENZLIN ME, MEIER C. Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol. 2011;7(11):647-656.
[10] REID IR. Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol. 2015; 11(7):418-428.
[11] WHITAKER M, GUO J, KEHOE T, et al. Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med. 2012;366(22):2048-2051.
[12] FENG X, MCDONALD JM. Disorders of bone remodeling. Annu Rev Pathol. 2011;6:121-145.
[13] CHAKRABORTY S, KUBATZKY KF, MITRA DK. An Update on Interleukin-9: From Its Cellular Source and Signal Transduction to Its Role in Immunopathogenesis. Int J Mol Sci. 2019;20(9):2113.
[14] GOSWAMI R, KAPLAN MH. A brief history of IL-9. J Immunol. 2011;186(6):3283-3288.
[15] NOELLE RJ, NOWAK EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol. 2010;10(10):683-687.
[16] GENG W, ZHANG W, MA J. IL-9 exhibits elevated expression in osteonecrosis of femoral head patients and promotes cartilage degradation through activation of JAK-STAT signaling in vitro. Int Immunopharmacol. 2018;60:228-234.
[17] ZHENG Y, HE Y, XIAO M, et al. Interleukin 9 prevents immune thrombocytopenia in mice via JAK/STAT5 signaling. Exp Cell Res. 2020; 88(1):111801.
[18] 邹旺辉,钱楠楠,张萌,等.间充质干细胞临床前研究启示:间充质干细胞的细胞功能与JAK/STAT信号通路的关系[J]. 中国组织工程研究,2022,26(19):3048-3055.
[19] SANPAOLO ER, ROTONDO C, CICI D, et al. JAK/STAT pathway and molecular mechanism in bone remodeling. Mol Biol Rep. 2020;47(11):9087-9096.
[20] ZHOU S, DAI Q, HUANG X, et al. STAT3 is critical for skeletal development and bone homeostasis by regulating osteogenesis. Nat Commun. 2021;12(1):6891.
[21] LEE J, SEONG S, KIM JH, et al. STAT5 is a key transcription factor for IL-3-mediated inhibition of RANKL-induced osteoclastogenesis. Sci Rep. 2016;6:30977.
[22] ZHAO Y, XIE L. Unique bone marrow blood vessels couple angiogenesis and osteogenesis in bone homeostasis and diseases. Ann N Y Acad Sci. 2020;1474(1):5-14.
[23] DATTA HK, NG WF, WALKER JA, et al. The cell biology of bone metabolism. J Clin Pathol. 2008; 61(5):577-587.
[24] KATSIMBRI P. The biology of normal bone remodelling. Eur J Cancer Care (Engl). 2017;26(6). doi: 10.1111/ecc.12740.
[25] RAGGATT LJ, PARTRIDGE NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010;285(33):25103-25108.
[26] SIDDIQUI JA, PARTRIDGE NC. Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement. Physiology (Bethesda). 2016;31(3):233-245.
[27] BATOON L, MILLARD SM, RAGGATT LJ, et al. Osteal macrophages support osteoclast-mediated resorption and contribute to bone pathology in a postmenopausal osteoporosis mouse model. J Bone Miner Res. 2021; 36(11):2214-2228.
[28] MCNAMARA LM. Osteocytes and Estrogen Deficiency. Curr Osteoporos Rep. 2021;19(6):592-603.
[29] FöGER-SAMWALD U, KERSCHAN-SCHINDL K, BUTYLINA M, et al. Age Related Osteoporosis: Targeting Cellular Senescence. Int J Mol Sci. 2022;23(5):2701.
[30] SCHETT G. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur J Clin Invest. 2011;41(12):1361-1366.
[31] ZUPAN J, JERAS M, MARC J. Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts. Biochem Med (Zagreb). 2013;23(1):43-63.
[32] RAUBER S, LUBER M, WEBER S, et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat Med. 2017;23(8):938-944.
[33] KAR S, GUPTA R, MALHOTRA R, et al. Interleukin-9 Facilitates Osteoclastogenesis in Rheumatoid Arthritis. Int J Mol Sci. 2021;22(19):10397.
[34] CHAKRABORTY S, SCHNEIDER J, MITRA DK, et al. Mechanistic insight of interleukin-9 induced osteoclastogenesis. Immunology. 2023;169(3):309-322.